-
1Academic Journal
Συγγραφείς: E. L. Nasonov, Е. Л. Насонов
Πηγή: Rheumatology Science and Practice; Vol 56, No 1 (2018); 5-9 ; Научно-практическая ревматология; Vol 56, No 1 (2018); 5-9 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20181
Θεματικοί όροι: иммуноопосредованные нежелательные реакции (immune related adverse evenеs), programmed death-1 (PD1), immune-mediated adverse reactions (immune related adverse events), рецептор программируемой смерти 1 (programmed death-1 – PD1)
Περιγραφή αρχείου: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/2492/1650; Rosenblum MD, Remedios KA, Abbas AK. Mechanisms of human autoimmunity. J Clin Invest. 2015;125(6):2228-33. doi:10.1172/JCI78088; Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13:227-42. doi:10.1038/nri3405; Насонов ЕЛ. Абатацепт при ревматоидном артрите: новая форма, новые механизмы, новые возможности. Научно-практическая ревматология. 2015;53(5):522-41 [Nasonov EL. Abatacept for rheumatoid arthritis: A novel formulation, new mechanisms, new possibilities. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(5):522-41 (In Russ.)]. doi:10.14412/1995-4484-2015-522-541; Buchbinder EI, Desari A. CTLA-4 and PD-1 pathways. Similarities, differences, and implications of their inhibition. Amer J Clin Oncol. 2016;39(1):98-106. doi:10.1097/COC.0000000000000239; Padrol DM. The blockade on immune checkpoints in cancer immunotherapy. Nat Rev Immunol. 2012;12:252-64. doi:10.1038/nrc3239; June CH, Warshauer JT, Bluestone JA. Is autoimmunity the Achilles' heel of cancer immunotherapy? Nat Med. 2017 May 5;23(5):540-7. doi:10.1038/nm.4321; Cousin S, Italiano A. Molecular pathways: immune checkpoint antibodies and their toxicities. Clin Cancer Res. 2016;22:4550-5. doi:10.1158/1078-0432.CCR-15-2569; Yoest JM. Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review. Immunotargets Ther. 2017;6:73-82. doi:10.2147/ITT.S126227; Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139-48. doi:10.1016/j.ejca.2015.11.016; Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of antiPD-1 therapy. Eur J Cancer. 2016;60:210-25. doi:10.1016/j.ejca.2016.02.024; Kostine M, Rouxel L, Barnetche T, et al; FHU ACRONIM. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis. 2017 Nov 16. doi:10.1136/annrheumdis-2017212257; Cappelli LC, Shah AA, Bingham CO 3rd. Immune-Related Adverse Effects of Cancer Immunotherapy – Implications for Rheumatology. Rheum Dis Clin North Am. 2017;43(1):65-78. doi:10.1016/j.rdc.2016.09.007; Cappelli LC, Gutierrez AK, Bingham CO, et al. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res. 2017;69:1751-63. doi:10.1002/acr.23177; Calabrese C, Kirchner E, Kontzias K, et al. Rheumatic immunerelated adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open. 2017;3(1):e000412. doi:10.1136/rmdopen-2016-000412; Suarez-Almazor ME, Kim ST, Abdel-Wahab N, et al. Review: immune-related adverse events with use of checkpoint inhibitors for immunotherapy of cancer. Arthritis Rheum. 2017;69:687-99. doi:10.1002/art.40043; Naidoo J, Cappelli LC, Forde PM, et al. Inflammatory arthritis: a newly recognized adverse event of immune checkpoint blockade. Oncologist. 2017;22:627-30. doi:10.1634/theoncologist.2016-0390; Rutgers A, van den Brom RRH, Hospers GAP, et al. Systemic vasculitis developed after immune checkpoint inhibition. Arthritis Care Res (Hoboken). 2017 Dec 1. doi:10.1002/acr.23481; Goldstein BL, Gedmintas L, Todd DJ. Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of CTLA-4. Arthritis Rheum. 2014;66:768-9. doi:10.1002/art.38282; De Velasco G, Bermas B, Choueiri TK. Autoimmune arthropathy and uveitis as complications of programmed death 1 inhibitor treatment. Arthritis Rheum. 2016;68:556-7. doi:10.1002/art.39406; Cappelli LC, Gutierrez AK, Baer AN, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 2017;76:43-50. doi:10.1136/annrheumdis-2016-209595; Chan MM, Kefford RF, Carlino M, et al. Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. J Immunother. 2015;38:37-9. doi:10.1097/CJI.0000000000000060; Law-Ping-Man S, Martin A, Briens E, et al. Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer. Rheumatology (Oxford). 2016;55:2087-9. doi:10.1093/rheumatology/kew281; Zhang H, Watanabe R, Berry GJ, et al. Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. Proc Natl Acad Sci U S A. 2017;114: E970-9. doi:10.1073/pnas.1616848114; Bilen MA, Subudhi SK, Gao J, et al. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J Immunother Cancer. 2016;4:36. doi:10.1186/s40425-016-0139-8; Belkhir R, Burel SL, Dunogeant L, et al. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis. 2017;76:1747-50. doi:10.1136/annrheumdis-2017-211216; Bonigen J, Raynaud-Donzel C, Hureaux J, et al. Anti-PD1induced psoriasis: a study of 21 patients. J Eur Acad Dermatol Venereol. 2017;31:e254-7. doi:10.1111/jdv.14011; Garel B, Kramkimel N, Trouvin AP, et al. Pembrolizumabinduced polymyalgia rheumatica in two patients with metastatic melanoma. Joint Bone Spine. 2017;84:233-4. doi:10.1016/j.jbspin.2016.01.007; Lidar M, Giat E, Garelick D, et al. Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev. 2018 Jan 13. pii: S1568-9972(18)30010-7. doi:10.1016/j.autrev.2018.01.003; Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2:1346-53. doi:10.1001/jamaoncol.2016.1051; Giat E, Ehrenfeld M, Shoenfeld Y. Cancer and autoimmune diseases. Autoimmun Rev. 2017 July 12. doi:10.1016/j.autrev.2017.07.022; Van der Vlist M, Kuball J, Radstake TR, Meyaard L. Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us? Nat Rev Rheumatol. 2016;12(10):593604. doi:10.1038/nrrheum.2016.131; Ma W-T, Chang C, Gershwin ME, Lian Z-X. Development of autoantibodies preceded clinical manifestations of autoimmune diseases: a comprehensive review. J Autoimmun. 2017;83:95-112. doi:10.1016/j.jaut.2017.07.003; Kim ST, Tayar J, Trinh VA, et al. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Ann Rheum Dis. 2017;76(12):2061-4. doi:10.1136/annrheumdis2017-211560; Esfahani K, Miller WH. Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade. N Engl J Med. 2017;376:1989-91. doi:10.1056/NEJMc1703047; Bertrand F, Montfort A, Marcheteau E, et al. TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma. Nat Commun. 2017;8(1):2256. doi:10.1038/s41467-017-02358-7